Free Trial

Relay Therapeutics (RLAY) Competitors

Relay Therapeutics logo
$3.62 +0.01 (+0.14%)
Closing price 03:59 PM Eastern
Extended Trading
$3.64 +0.02 (+0.41%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RLAY vs. AMRX, OGN, APLS, XENE, IBRX, BHC, AGIO, CNTA, BEAM, and TWST

Should you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include Amneal Pharmaceuticals (AMRX), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), ImmunityBio (IBRX), Bausch Health Cos (BHC), Agios Pharmaceuticals (AGIO), Centessa Pharmaceuticals (CNTA), Beam Therapeutics (BEAM), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry.

Relay Therapeutics vs. Its Competitors

Relay Therapeutics (NASDAQ:RLAY) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Relay Therapeutics presently has a consensus target price of $17.67, suggesting a potential upside of 387.36%. Amneal Pharmaceuticals has a consensus target price of $11.60, suggesting a potential upside of 43.65%. Given Relay Therapeutics' higher probable upside, equities analysts plainly believe Relay Therapeutics is more favorable than Amneal Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Relay Therapeutics
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.83
Amneal Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

Amneal Pharmaceuticals has higher revenue and earnings than Relay Therapeutics. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relay Therapeutics$10.01M62.09-$337.71M-$2.23-1.63
Amneal Pharmaceuticals$2.79B0.91-$116.89M-$0.04-201.88

Relay Therapeutics has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500.

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 4.3% of Relay Therapeutics shares are held by company insiders. Comparatively, 17.5% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Relay Therapeutics has a net margin of 0.00% compared to Amneal Pharmaceuticals' net margin of -0.46%. Relay Therapeutics' return on equity of -44.17% beat Amneal Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Relay TherapeuticsN/A -44.17% -39.53%
Amneal Pharmaceuticals -0.46%-188.26%5.34%

In the previous week, Relay Therapeutics had 2 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 5 mentions for Relay Therapeutics and 3 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.37 beat Relay Therapeutics' score of 0.93 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Relay Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Amneal Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Relay Therapeutics beats Amneal Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Relay Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RLAY vs. The Competition

MetricRelay TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$621.51M$2.46B$5.59B$9.53B
Dividend YieldN/A1.77%4.71%4.03%
P/E Ratio-1.639.4927.9619.93
Price / Sales62.09427.91389.5465.88
Price / CashN/A165.5736.3258.75
Price / Book0.784.968.375.77
Net Income-$337.71M$31.62M$3.25B$259.10M
7 Day Performance-4.35%-3.27%-2.50%-3.41%
1 Month Performance4.77%9.78%7.98%8.53%
1 Year Performance-56.17%-5.75%34.65%15.75%

Relay Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RLAY
Relay Therapeutics
2.1594 of 5 stars
$3.63
+0.1%
$17.67
+387.4%
-55.9%$621.51M$10.01M-1.63330News Coverage
Upcoming Earnings
AMRX
Amneal Pharmaceuticals
2.9367 of 5 stars
$7.91
-0.8%
$11.60
+46.6%
+10.2%$2.48B$2.79B-197.708,100News Coverage
Positive News
OGN
Organon & Co.
4.8816 of 5 stars
$9.43
-0.4%
$18.00
+91.0%
-54.9%$2.45B$6.40B3.274,000Positive News
Upcoming Earnings
APLS
Apellis Pharmaceuticals
4.385 of 5 stars
$19.28
-1.0%
$40.00
+107.5%
-51.8%$2.42B$781.37M-10.77770Upcoming Earnings
Analyst Forecast
Analyst Revision
XENE
Xenon Pharmaceuticals
3.7204 of 5 stars
$31.49
-0.3%
$54.82
+74.1%
-29.6%$2.42B$9.43M-9.75210Positive News
IBRX
ImmunityBio
2.1753 of 5 stars
$2.68
-2.5%
$12.25
+357.1%
-53.2%$2.37B$14.74M-4.62590
BHC
Bausch Health Cos
3.785 of 5 stars
$6.34
+0.4%
$7.30
+15.2%
+14.8%$2.34B$9.63B-57.6020,700News Coverage
AGIO
Agios Pharmaceuticals
4.3879 of 5 stars
$39.92
-0.2%
$58.60
+46.8%
-20.5%$2.31B$37.04M3.55390News Coverage
Upcoming Earnings
Analyst Forecast
CNTA
Centessa Pharmaceuticals
3.3572 of 5 stars
$16.06
+2.4%
$28.10
+75.0%
+42.8%$2.14B$6.85M-8.87200Positive News
BEAM
Beam Therapeutics
2.2946 of 5 stars
$21.03
+1.3%
$48.75
+131.8%
-37.8%$2.11B$63.52M-4.56510Upcoming Earnings
Gap Up
TWST
Twist Bioscience
4.4795 of 5 stars
$34.77
-1.1%
$50.40
+45.0%
-39.6%$2.08B$312.97M-10.70990Positive News
Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:RLAY) was last updated on 7/30/2025 by MarketBeat.com Staff
From Our Partners